No profile data available.
Climb Bio Inc (CLYM) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Wellesley Hills, United States, with about 28 full-time employees.
In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $631.80 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
$631.80 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Alumis Inc. (ALMS), Rigel Pharmaceuticals, Inc. (RIGL), Monte Rosa Therapeutics, Inc. (GLUE), Shattuck Labs, Inc. (STTK).